US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
US4018653A
(en)
|
1971-10-29 |
1977-04-19 |
U.S. Packaging Corporation |
Instrument for the detection of Neisseria gonorrhoeae without culture
|
US4044126A
(en)
|
1972-04-20 |
1977-08-23 |
Allen & Hanburys Limited |
Steroidal aerosol compositions and process for the preparation thereof
|
GB1429184A
(en)
|
1972-04-20 |
1976-03-24 |
Allen & Hanburys Ltd |
Physically anti-inflammatory steroids for use in aerosols
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
US4016043A
(en)
|
1975-09-04 |
1977-04-05 |
Akzona Incorporated |
Enzymatic immunological method for the determination of antigens and antibodies
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
US4328245A
(en)
|
1981-02-13 |
1982-05-04 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
US4410545A
(en)
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
US4409239A
(en)
|
1982-01-21 |
1983-10-11 |
Syntex (U.S.A.) Inc. |
Propylene glycol diester solutions of PGE-type compounds
|
US4424279A
(en)
|
1982-08-12 |
1984-01-03 |
Quidel |
Rapid plunger immunoassay method and apparatus
|
ES8702440A1
(es)
|
1984-10-04 |
1986-12-16 |
Monsanto Co |
Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
US5310652A
(en)
|
1986-08-22 |
1994-05-10 |
Hoffman-La Roche Inc. |
Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
|
US5322770A
(en)
|
1989-12-22 |
1994-06-21 |
Hoffman-Laroche Inc. |
Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
|
US5561058A
(en)
|
1986-08-22 |
1996-10-01 |
Hoffmann-La Roche Inc. |
Methods for coupled high temperatures reverse transcription and polymerase chain reactions
|
US5693517A
(en)
|
1987-06-17 |
1997-12-02 |
Roche Molecular Systems, Inc. |
Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions
|
IE72468B1
(en)
|
1987-07-31 |
1997-04-09 |
Univ Leland Stanford Junior |
Selective amplification of target polynucleotide sequences
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
CA1340807C
(en)
|
1988-02-24 |
1999-11-02 |
Lawrence T. Malek |
Nucleic acid amplification process
|
US4870287A
(en)
|
1988-03-03 |
1989-09-26 |
Loma Linda University Medical Center |
Multi-station proton beam therapy system
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
PH30995A
(en)
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
CA2020958C
(en)
|
1989-07-11 |
2005-01-11 |
Daniel L. Kacian |
Nucleic acid sequence amplification methods
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
US5420245A
(en)
|
1990-04-18 |
1995-05-30 |
Board Of Regents, The University Of Texas |
Tetrapeptide-based inhibitors of farnesyl transferase
|
US5976851A
(en)
|
1990-04-18 |
1999-11-02 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the identification, characterization, and inhibition of farnesyl protein transferase
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
IE913930A1
(en)
|
1990-11-13 |
1992-06-17 |
Siska Diagnostics |
Nucleic acid amplification by two-enzyme, self-sustained¹sequence replication
|
US5455166A
(en)
|
1991-01-31 |
1995-10-03 |
Becton, Dickinson And Company |
Strand displacement amplification
|
US5238922A
(en)
|
1991-09-30 |
1993-08-24 |
Merck & Co., Inc. |
Inhibitors of farnesyl protein transferase
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
JP3645903B2
(ja)
|
1992-03-04 |
2005-05-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
比較ゲノムハイブリダイゼーション(cgh)
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
US5686472A
(en)
|
1992-10-29 |
1997-11-11 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5504212A
(en)
|
1992-10-29 |
1996-04-02 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
TW333456B
(en)
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
WO1994026723A2
(en)
|
1993-05-14 |
1994-11-24 |
Genentech, Inc. |
ras FARNESYL TRANSFERASE INHIBITORS
|
US5965539A
(en)
|
1993-05-18 |
1999-10-12 |
Univeristy Of Pittsburgh |
Inhibitors of prenyl transferases
|
US5602098A
(en)
|
1993-05-18 |
1997-02-11 |
University Of Pittsburgh |
Inhibition of farnesyltransferase
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
US5721236A
(en)
|
1993-10-15 |
1998-02-24 |
Schering Corporation |
Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
|
US5523430A
(en)
|
1994-04-14 |
1996-06-04 |
Bristol-Myers Squibb Company |
Protein farnesyl transferase inhibitors
|
FR2721021B1
(fr)
|
1994-06-10 |
1996-07-12 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnésyl transférase, leur préparation et les compositions pharmaceutique qui les contiennent.
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
US5491063A
(en)
|
1994-09-01 |
1996-02-13 |
Hoffmann-La Roche Inc. |
Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
|
US5585359A
(en)
|
1994-09-29 |
1996-12-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5491164A
(en)
|
1994-09-29 |
1996-02-13 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5661161A
(en)
|
1994-09-29 |
1997-08-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5571673A
(en)
|
1994-11-23 |
1996-11-05 |
Hoffmann-La Roche Inc. |
Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
|
FR2729390A1
(fr)
|
1995-01-18 |
1996-07-19 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
FR2730491B1
(fr)
|
1995-02-09 |
1997-03-14 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
US5684013A
(en)
|
1995-03-24 |
1997-11-04 |
Schering Corporation |
Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
|
US5700806A
(en)
|
1995-03-24 |
1997-12-23 |
Schering Corporation |
Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
|
US5856326A
(en)
|
1995-03-29 |
1999-01-05 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5534537A
(en)
|
1995-03-29 |
1996-07-09 |
Merck & Co., Inc. |
Prodrugs of inhibitors of farnesyl-protein transferase
|
US5578629A
(en)
|
1995-03-29 |
1996-11-26 |
Merck & Co., Inc. |
Benzamide-containing inhibitors of farnesyl-protein transferase
|
US5972984A
(en)
|
1995-06-06 |
1999-10-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5756528A
(en)
|
1995-06-06 |
1998-05-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2224381A1
(en)
|
1995-06-27 |
1997-01-16 |
Takeda Chemical Industries, Ltd. |
Method of producing sustained-release preparation
|
FR2736641B1
(fr)
|
1995-07-10 |
1997-08-22 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
FR2736638B1
(fr)
|
1995-07-12 |
1997-08-22 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
TW448055B
(en)
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
JP2909418B2
(ja)
|
1995-09-18 |
1999-06-23 |
株式会社資生堂 |
薬物の遅延放出型マイクロスフイア
|
TW349948B
(en)
|
1995-10-31 |
1999-01-11 |
Janssen Pharmaceutica Nv |
Farnesyl transferase inhibiting 2-quinolone derivatives
|
AU711142B2
(en)
|
1995-12-08 |
1999-10-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives
|
US5874442A
(en)
|
1995-12-22 |
1999-02-23 |
Schering-Plough Corporation |
Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
|
US5980945A
(en)
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
US5968965A
(en)
|
1996-01-30 |
1999-10-19 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6011029A
(en)
|
1996-02-26 |
2000-01-04 |
Bristol-Myers Squibb Company |
Inhibitors of farnesyl protein transferase
|
AU707139B2
(en)
|
1996-04-03 |
1999-07-01 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5852010A
(en)
|
1996-04-03 |
1998-12-22 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5869682A
(en)
|
1996-04-03 |
1999-02-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5880140A
(en)
|
1996-04-03 |
1999-03-09 |
Merck & Co., Inc. |
Biheteroaryl inhibitors of farnesyl-protein transferase
|
US5891889A
(en)
|
1996-04-03 |
1999-04-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5939557A
(en)
|
1996-04-03 |
1999-08-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5780492A
(en)
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5965578A
(en)
|
1996-04-03 |
1999-10-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
WO1997038697A1
(en)
|
1996-04-15 |
1997-10-23 |
The Trustees Of The University Of Pennsylvania |
Sensitization of cells to radiation and chemotherapy
|
US5760395A
(en)
|
1996-04-18 |
1998-06-02 |
Universities Research Assoc., Inc. |
Method and apparatus for laser-controlled proton beam radiology
|
US6264970B1
(en)
|
1996-06-26 |
2001-07-24 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
US5767274A
(en)
|
1996-06-28 |
1998-06-16 |
Biomeasure, Incorporated |
Prenyl transferase inhibitors
|
US5773455A
(en)
|
1996-06-28 |
1998-06-30 |
Biomeasure, Incorporated |
Inhibitors of prenyl transferases
|
US6419961B1
(en)
|
1996-08-29 |
2002-07-16 |
Takeda Chemical Industries, Ltd. |
Sustained release microcapsules of a bioactive substance and a biodegradable polymer
|
KR100232231B1
(ko)
|
1996-09-13 |
2000-03-02 |
김영환 |
비휘발성 메모리 소자의 데이터 기입 장치 및 방법
|
CA2217134A1
(en)
|
1996-10-09 |
1998-04-09 |
Sumitomo Pharmaceuticals Co., Ltd. |
Sustained release formulation
|
ATE272394T1
(de)
|
1996-10-31 |
2004-08-15 |
Takeda Chemical Industries Ltd |
Zubereitung mit verzögerter freisetzung
|
US5972966A
(en)
|
1996-12-05 |
1999-10-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
ZA9711385B
(en)
|
1996-12-20 |
1999-06-18 |
Takeda Chemical Industries Ltd |
Method of producing a sustained-release preparation
|
ATE252104T1
(de)
|
1996-12-20 |
2003-11-15 |
Tovarischestvo S Ogranichennoi |
Verfahren und gerät zur herstellung von 1ss, 10ss-epoxy-13-dimethylamino-guaia-3(4)-en-6,12- lid- hydrochlorid
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
TW591030B
(en)
|
1997-03-10 |
2004-06-11 |
Janssen Pharmaceutica Nv |
Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
|
NZ336233A
(en)
|
1997-04-25 |
2001-01-26 |
Janssen Pharmaceutica Nv |
Phenyl substituted quinazolines on 4-position and 2-quinazolinone moiety bearing a carbon or nitrogen-linked imidazolyl moiety
|
IL133212A
(en)
|
1997-06-02 |
2005-12-18 |
Janssen Pharmaceutica Nv |
History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells
|
BR9906903A
(pt)
|
1998-01-16 |
2000-12-12 |
Takeda Chemical Industries Ltd |
Composição com liberação sustentada, processos para produzir a mesma, para suprimir a brusca liberação inicial da susbtância bioativa de uma composição com liberação sustentada e para aumentar a eficiência da inclusão da substância bioativa em uma composição com liberação sustentada, produto farmacêutico, agente para prevenir ou tratar câncer prostático, hipertrofia prostática, endometriose, histeromioma, metrofibroma, puberdade precoce, dismenorréia, ou câncer do seio, ou um contraceptivo, e, composto
|
CA2322798C
(en)
|
1998-03-05 |
2008-05-13 |
Formula One Administration Limited |
Data communication system
|
US6303654B1
(en)
|
1998-03-12 |
2001-10-16 |
Wisconsin Alumni Research Foundation |
Acyclic monoterpenoid derivatives
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
KR19990085365A
(ko)
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
AU5086499A
(en)
|
1998-07-01 |
2000-01-24 |
Merck & Co., Inc. |
Process for making farnesyl-protein transferase inhibitors
|
SK284723B6
(sk)
|
1998-07-06 |
2005-10-06 |
Janssen Pharmaceutica N. V. |
Použitie inhibítora farnesyl-proteín transferázy na prípravu farmaceutickej kompozície, majúcej rádiosenzibilizačné vlastnosti
|
PT1094815E
(pt)
|
1998-07-06 |
2004-04-30 |
Janssen Pharmaceutica Nv |
Inibidores da proteina farnesil transferase para tratamento de artropatias
|
ES2259237T3
(es)
|
1998-08-27 |
2006-09-16 |
Pfizer Products Inc. |
Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos.
|
CA2341739C
(en)
|
1998-08-27 |
2005-07-12 |
Pfizer Products Inc. |
Quinolin-2-one derivatives useful as anticancer agents
|
US6927024B2
(en)
|
1998-11-30 |
2005-08-09 |
Genentech, Inc. |
PCR assay
|
KR100712226B1
(ko)
|
1998-12-23 |
2007-04-27 |
얀센 파마슈티카 엔.브이. |
1,2-어닐링된 퀴놀린 유도체
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US20040157882A1
(en)
|
1999-11-30 |
2004-08-12 |
End David William |
Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation
|
US7186507B2
(en)
|
1999-12-09 |
2007-03-06 |
Indiana University Research And Technology Corporation |
Fluorescent in situ RT-PCR
|
PT1255537E
(pt)
|
2000-02-04 |
2006-09-29 |
Janssen Pharmaceutica Nv |
Inibidores da proteina farnesil transferase para tratar cancro da mama
|
CA2397558A1
(en)
|
2000-02-24 |
2001-08-30 |
Janssen Pharmaceutica N.V. |
Dosing regimen
|
JO2361B1
(en)
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
EP1339407B1
(en)
|
2000-11-28 |
2006-04-19 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
|
JP4969016B2
(ja)
|
2001-02-15 |
2012-07-04 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
|
US7101663B2
(en)
|
2001-03-02 |
2006-09-05 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
PCR method
|
PL208238B1
(pl)
|
2001-03-12 |
2011-04-29 |
Janssen Pharmaceutica Nv |
Sposób wytwarzania 4- (3-chlorofenylo) -6- [ (4-chlorofenylo) hydroksy (1-metylo-1H-imidazol-5-ilo) metylo] -1-metylo-2 (1H) -chinolinonu
|
JP2004526776A
(ja)
|
2001-04-25 |
2004-09-02 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
悪液質を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤
|
CA2451168A1
(en)
|
2001-10-30 |
2003-05-08 |
Ortho-Clinical Diagnostics, Inc. |
Methods for assessing and treating leukemia
|
WO2003080058A1
(en)
|
2002-03-22 |
2003-10-02 |
Janssen Pharmaceutica. N.V. |
Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7122799B2
(en)
|
2003-12-18 |
2006-10-17 |
Palo Alto Research Center Incorporated |
LED or laser enabled real-time PCR system and spectrophotometer
|
JP4917022B2
(ja)
|
2004-05-03 |
2012-04-18 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
6−ブロモ−4−(3−クロロフェニル)−2−メトキシ−キノリンを用いるジアステレオ選択的合成方法
|
ES2308500T3
(es)
|
2004-05-03 |
2008-12-01 |
Janssen Pharmaceutica Nv |
Adicion diastereoselectiva de n-metilimidazol en sulfiniminas.
|
ES2308486T3
(es)
|
2004-05-03 |
2008-12-01 |
Janssen Pharmaceutica Nv |
Proceso de sintesis diastereoselectiva para la preparacion de compuestos de imidazol.
|
DK2362218T3
(en)
|
2004-11-05 |
2014-11-17 |
Janssen Pharmaceutica Nv |
Methods for monitoring the effectiveness of farnesyl transferase
|
AU2006341131A1
(en)
|
2005-10-14 |
2007-10-04 |
Janssen Pharmaceutica, N.V. |
Formulations of tipifarnib for intravenous administration
|
US7932036B1
(en)
|
2008-03-12 |
2011-04-26 |
Veridex, Llc |
Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
|
MX2010013281A
(es)
|
2008-06-03 |
2010-12-21 |
Janssen Pharmaceutica Nv |
Peptido mimetico de trombopoyetina para prevenir trastornos hematologicos asociados con el tratamiento del cancer.
|
US11559540B2
(en)
|
2010-07-28 |
2023-01-24 |
Janssen Pharmaceutica Nv |
Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
|
CN106244707A
(zh)
|
2010-07-28 |
2016-12-21 |
维里德克斯有限责任公司 |
急性髓细胞性白血病应答法尼基转移酶抑制剂治疗的测定方法
|
WO2014160130A1
(en)
|
2013-03-13 |
2014-10-02 |
Oncoceutics, Inc. |
Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
|
AU2015249225B2
(en)
*
|
2014-04-25 |
2019-11-07 |
Memorial Sloan-Kettering Cancer Center |
Treatment of H-Ras-driven tumors
|
ES2901506T3
(es)
|
2015-08-17 |
2022-03-22 |
Kura Oncology Inc |
Métodos para tratar pacientes con cáncer con inhibidores de la farnesiltransferasa
|
PT3534885T
(pt)
|
2016-11-03 |
2021-04-13 |
Kura Oncology Inc |
Inibidores de farnesiltransferase para usar em métodos de tratamento do cancro
|